UCB's Global Corporate Website
Welcome to UCB in the United States

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Oct

10

Using Data and Technology to Enable Better Patient Care

UCB has been rapidly investing in our digital business transformation to unleash the power of digital innovation to help achieve better outcomes for patients, faster.

Sep

07

New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Aug

11

Setting New Standards in Diversity for Dermatology Clinical Trials

One place where we can learn more about psoriasis in people of color is in clinical trials. However, people with skin of color are drastically underrepresented in clinical trials for dermatology. The lack of diversity in clinical trials means that medications developed for conditions like psoriasis may not work as effectively for people with skin of color, and ultimately, the health equity gap continues to widen.

 

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

25

UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

 

 

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms